Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07330778 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
A Phase 1 study of Mild to Moderate Asthma, sponsored by Celldex Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07330778 is a Phase 1 study of Mild to Moderate Asthma that is actively recruiting participants, run by Celldex Therapeutics. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07330778, a Phase 1 study of Mild to Moderate Asthma, is actively recruiting participants, sponsored by Celldex Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Conditions Studied
Interventions
- DRUG CDX-622
Study Locations (1)
Kansas
- The University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07330778
The ClinicalTrials.gov registry entry for NCT07330778 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild to Moderate Asthma appearing as the primary indexed condition, and to 1 intervention - of which CDX-622 is the first listed.
NCT07330778 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT07330778 about?
NCT07330778 is a clinical study titled "A Study of CDX-622 in Participants With Mild to Moderate Asthma". This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
What is the current status of trial NCT07330778?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02. Estimated completion is 2027-03.
What conditions does trial NCT07330778 study?
This clinical trial studies the following conditions: Mild to Moderate Asthma.
What interventions are being tested in trial NCT07330778?
The interventions under investigation include: CDX-622 (DRUG).
Who is sponsoring clinical trial NCT07330778?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07330778 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.